Amylyx Pharmaceuticals (AMLX) Net Margin (2021 - 2024)
Historic Net Margin for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Q4 2024 value amounting to 141.71%.
- Amylyx Pharmaceuticals' Net Margin fell 1452700.0% to 141.71% in Q4 2024 from the same period last year, while for Sep 2025 it was 567.71%, marking a year-over-year decrease of 4478700.0%. This contributed to the annual value of 263.74% for FY2024, which is 2751100.0% down from last year.
- Latest data reveals that Amylyx Pharmaceuticals reported Net Margin of 141.71% as of Q4 2024, which was down 1452700.0% from 17476.92% recorded in Q3 2024.
- Over the past 5 years, Amylyx Pharmaceuticals' Net Margin peaked at 20.36% during Q2 2023, and registered a low of 17476.92% during Q3 2024.
- In the last 4 years, Amylyx Pharmaceuticals' Net Margin had a median value of 141.71% in 2024 and averaged 3902.46%.
- Its Net Margin has fluctuated over the past 5 years, first skyrocketed by 98461000bps in 2023, then crashed by -174956000bps in 2024.
- Quarter analysis of 4 years shows Amylyx Pharmaceuticals' Net Margin stood at 8120.0% in 2021, then soared by 98bps to 164.94% in 2022, then skyrocketed by 102bps to 3.56% in 2023, then crashed by -4081bps to 141.71% in 2024.
- Its last three reported values are 141.71% in Q4 2024, 17476.92% for Q3 2024, and 7106.55% during Q2 2024.